Viking Therapeutics (VKTX) Cash from Operations (2014 - 2026)

Viking Therapeutics has disclosed Cash from Operations across 13 years of filings, most recently posting 113976000.0 for Q1 2026.

• Cash from Operations for Q1 2026 came in at 113976000.0, down 117.8% year-over-year; the trailing twelve-month figure through Mar 2026 was 340330000.0 (down 154.0% YoY), and the FY2025 annual result was 278685000.0, down 217.45% from the prior year.
• Cash from Operations came in at 113976000.0 for Q1 2026 at Viking Therapeutics, down from 85290000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 6134000.0 in Q1 2024 to a low of 113976000.0 in Q1 2026.
• The 5-year median for Cash from Operations is 21962000.0 (2024), against an average of 35424941.18.
• Across the five-year window, Cash from Operations soared 75.11% in 2024 and plunged 753.13% in 2025, its largest moves.
• Viking Therapeutics' Cash from Operations stood at 10926000.0 in 2022, then sank by 61.45% to 17640000.0 in 2023, then slumped by 76.76% to 31181000.0 in 2024, then plunged by 173.53% to 85290000.0 in 2025, then tumbled by 33.63% to 113976000.0 in 2026.
• The last three Cash from Operations figures came in at 113976000.0 (Q1 2026), 85290000.0 (Q4 2025), and 94003000.0 (Q3 2025), per Business Quant data.